RxDoctor Payments Data

Monette Lalimar, NP

Nurse Practitioner · Bakersfield, CANPI 1720147440

Payments from drug & device makers

$18,738in general payments, 2019–2025

Across 818 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$2K
  • Novartis$1K
  • UCB, Inc.$1K
  • EMD Serono, Inc.$941
  • Livanova USA, Inc.$919
  • plus $10K from 51 others

What the payments were for

  • Speaking & faculty fees$680%
  • Travel & lodging$1811%
  • Food & beverage$18,29898%
  • Education$1911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie143$2,067
Biogen58$1,602
Novartis76$1,487
UCB, Inc.49$1,271
EMD Serono, Inc.29$941
Livanova USA, Inc.16$919
Merz Pharmaceuticals, LLC30$761
Teva Pharmaceuticals USA, Inc.46$745
Neurelis, Inc.27$685
Neurocrine Biosciences, Inc.12$678
Eisai Inc.25$584
AstraZeneca(2 entities)20$582
Lundbeck LLC19$464
SK Life Science, Inc.25$417
Acorda Therapeutics, Inc19$368
Amgen(2 entities)12$355
Acadia Pharmaceuticals Inc19$346
Argenx US, Inc.12$343
Sumitomo Pharma America, Inc.17$343
Kyowa Kirin, Inc.14$304
Sanofi11$303
Lilly USA, LLC16$294
Otsuka America Pharmaceutical, Inc.8$255
Biohaven Pharmaceutical Holding Company Ltd.8$231
Pfizer9$178
Alnylam Pharmaceuticals Inc.3$176
Biohaven Pharmaceuticals, Inc.10$160
Sunovion Pharmaceuticals Inc.9$149
MDD US Operations, LLC15$136
Jazz Pharmaceuticals Inc.3$136
Sarepta Therapeutics, Inc.5$129
Takeda Pharmaceuticals U.S.A., Inc.5$107
Ipsen Biopharmaceuticals, Inc4$99
Immedica Pharma US, Inc.3$98
Johnson & Johnson(2 entities)5$96
Genentech USA, Inc.2$93
Janssen Scientific Affairs, LLC1$88
Abbott1$84
Amylyx Pharmaceuticals, Inc.5$82
TG Therapeutics, Inc.3$69
Impel Pharmaceuticals Inc.1$67
Boston Scientific2$57
ANI Pharmaceuticals, Inc.2$45
GRT US Holding, Inc.2$42
Scilex Pharmaceuticals Inc.2$40
Amneal Pharmaceuticals LLC2$36
Tanabe Pharma America, Inc.2$35
Banner Life Sciences, LLC2$29
Supernus Pharmaceuticals, Inc.1$24
Catalyst Pharmaceuticals, Inc.1$21
E.r. Squibb & Sons, L.L.C.1$20
CSL Behring1$19
Averitas Pharma Inc.1$17
Cycle Pharmaceuticals Inc1$16
Akcea Therapeutics, Inc.1$16
Sanofi-aventis U.S. LLC1$15
Zogenix Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,738 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$29,455
Medicare patients
93
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$103,841
Avonex Pen (4 Pack)Interferon Beta-1a12$98,660
AptiomEslicarbazepine Acetate23$46,679
Rufinamide14$22,683
QuliptaAtogepant13$13,952
TegretolCarbamazepine20$7,806
Levetiracetam147$7,432
Donepezil Hcl324$5,107
Lacosamide28$4,635
Memantine Hcl ErMemantine Hcl57$4,483
Carbamazepine ErCarbamazepine26$3,883
Gabapentin260$3,426
Quetiapine Fumarate100$3,375
Memantine Hcl205$3,075
Divalproex Sodium67$2,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$678$103,84111 claims
Sunovion Pharmaceuticals Inc.Aptiom$149$46,67923 claims
AbbVieQulipta$2,067$13,95213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →